Gowthami Morey Arepally, MD

Professor of Medicine
Associate Professor of Pathology
Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center and the Medical Director of Therapeutic Apheresis at Duke.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders.    Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT.  Current laboratory efforts focus on the role of complement activation in the immune pathogenesis of HIT, investigations of protamine/heparin antibodies and development of murine models for studies of the HIT immune response.  Clinical projects include applications of therapeutic apheresis, including development of a multi-site network for investigations of thrombotic microangiopathy.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Arepally, G. M., and I. M. Mayer. “Binding and activation of monocytes by PF4/heparin specific antibodies.” Blood 96, no. 11 (November 16, 2000): 269A-269A.

Scholars@Duke

Reilly, M. P., S. M. Taylor, N. K. Hartman, G. M. Arepally, D. B. Cines, M. Poncz, and S. E. McKenzie. “Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through Fc gamma RIIA.” Blood 96, no. 11 (November 16, 2000): 221A-221A.

Scholars@Duke

Arepally, G. M., S. Kamei, K. S. Park, K. Kamei, Z. Q. Li, W. Liu, D. L. Siegel, W. Kisiel, D. B. Cines, and M. Poncz. “Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.” Blood 95, no. 5 (March 1, 2000): 1533–40.

PMID
10688805
Scholars@Duke

Arepally, G. M. “Characterization of a monoclonal antibody to PF4/heparin (KKO) with functional and serologic properties of hit antibodies.” Blood 94, no. 10 (November 15, 1999): 21A-21A.

Scholars@Duke

Arepally, G. M., K. Kamei, W. Kisiel, D. B. Cines, and M. Poncz. “A murine monoclonal PF4/heparin-specific antibody that mimicks heparin-induced thrombocytopenia (HIT) antibodies.” Thrombosis and Haemostasis, August 1, 1999, 530–530.

Scholars@Duke

Blank, M., A. Eldor, S. Tavor, L. Ziporen, D. B. Cines, G. Arepally, A. Afek, and Y. Shoenfeld. “A mouse model for heparin-induced thrombocytopenia.” Seminars in Hematology 36, no. SUPPL. 1 (January 28, 1999): 12–16.

Scholars@Duke

Blank, M., A. Eldor, S. Tavor, L. Ziporen, D. B. Cines, G. Arepally, A. Afek, and Y. Shoenfeld. “A mouse model for heparin-induced thrombocytopenia.” Semin Hematol 36, no. 1 Suppl 1 (January 1999): 12–16.

PMID
9930558
Scholars@Duke

Ziporen, L., Z. Q. Li, K. S. Park, P. Sabnekar, W. Y. Liu, G. Arepally, Y. Shoenfeld, T. Kieber-Emmons, D. B. Cines, and M. Poncz. “Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.” Blood 92, no. 9 (November 1, 1998): 3250–59.

PMID
9787161
Scholars@Duke

Arepally, G., T. R. Rebbeck, W. Song, G. Gilliland, J. M. Maris, and M. Poncz. “Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML).” Blood 92, no. 7 (October 1, 1998): 2600–2602.

PMID
9746808
Scholars@Duke

Pages